Endo to pay $193M to wrap up Justice Department's off-label marketing probe

Sales whistleblowers have struck again, this time landing Endo Health Solutions ($ENDP) in a $193 million hole. The Malvern, PA-company is paying up to settle with the Department of Justice, which says it marketed Lidoderm, a patch approved to treat shingles pain, for off-label uses including pain from diabetic neuropathy and carpal tunnel syndrome. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.